← ANALYST RATINGS · TIPRANKS
Altimmune (ALT): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy1 Hold0 Sell
Ratings of 4 analysts in the last 3 months · top analysts only12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $15.00, the highest $20.00, the lowest $10.00. The average is +581.8% from the last price of $2.20.
Analyst ratings 12
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.50 → $2.00−20.0% | Hold | −9.1% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.50 → $2.00−20.0% | Hold | −9.1% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.50 → $2.00−20.0% | Hold | −9.1% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.50 → $2.00−20.0% | Hold | −9.1% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.00 → $2.50−16.7% | Hold | +13.6% | Reiterated | 09.10.26on TipRanks 16:05 | — | |
| Patrick Trucchio★★★★★★★★★★#79 · hits 58% · avg +37.9% | H.C. Wainwright | $20.00 | Buy | +809.1% | Reiterated | 08.10.26on TipRanks Oct 9 08:00 | −1.8%next day −0.2% · 5 days −9.0% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.00 → $2.50−16.7% | Hold | +13.6% | Reiterated | 06.10.26on TipRanks 01:05 | — | |
| Michael DiFiore★★★★★★★★★★#10315 · hits 56% · avg −8.0% | Evercore ISI | $18.00 → $17.00−5.6% | Buy | +672.7% | Reiterated | 24.09.26on TipRanks Sep 23 08:11 | −5.7%next day −4.6% · 5 days −9.7% | ↗ |
| Unknown Analyst | Jefferies | $28.00 | Buy | +1,172.7% | Reiterated | 13.08.26on TipRanks Aug 17 06:31 | −2.4%next day +2.3% · 5 days +4.4% | ↗ |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $20.00 | Buy | +809.1% | Reiterated | 13.08.26on TipRanks 04:25 | −2.4%next day +2.3% · 5 days +4.4% | ↗ |
| Andy Hsieh★★★★★★★★★★#1805 · hits 48% · avg +9.0% | William Blair | — | Hold | — | Reiterated | 12.08.26on TipRanks 12:35 | −2.6%next day −2.4% · 5 days +6.9% | ↗ |
| Srikripa Devarakonda★★★★★★★★★★#200 · hits 62% · avg +26.3% | Truist Financial | — | Buy | — | Reiterated | 29.07.26on TipRanks 10:39 | −0.8%next day +0.4% · 5 days −1.8% | ↗ |
| Thomas Smith★★★★★★★★★★#45 · hits 57% · avg +51.1% | Leerink Partners | $10.00 | Buy | +354.5% | Reiterated | 28.07.26on TipRanks 10:21 | +0.8%next day −0.8% · 5 days −1.4% | ↗ |
| Jonathan Wolleben★★★★★★★★★★#249 · hits 53% · avg +23.6% | Citizens JMP | $14.00 → $11.00−21.4% | Buy | +400.0% | Reiterated | 14.05.26on TipRanks 05:50 | −4.1%next day −1.2% · 5 days +1.1% | ↗ |
| Corinne Johnson★★★★★★★★★★#1634 · hits 55% · avg +11.6% | Goldman Sachs | $1.00 → $2.50+150.0% | Hold | +13.6% | Upgrade | 24.04.26on TipRanks 13:25 | −2.2%next day −1.9% · 5 days −2.0% | ↗ |
| William Wood★★★★★★★★★★#3198 · hits 53% · avg +11.7% | B. Riley Securities | $18.00 → $13.00−27.8% | Buy | +490.9% | Reiterated | 06.03.26on TipRanks 08:35 | +2.3%next day +8.7% · 5 days +0.4% | ↗ |
| Boris Peaker★★★★★★★★★★#357 · hits 49% · avg +22.6% | JonesTrading | $7.00 | Buy | +218.2% | Initiated | 13.02.26on TipRanks 10:00 | −0.9%next day −0.8% · 5 days −0.3% | ↗ |
| Annabel Samimy★★★★★★★★★★#421 · hits 51% · avg +19.3% | Stifel Nicolaus | — | Buy | — | Reiterated | 19.12.25on TipRanks Dec 21 20:25 | −23.7%next day +5.5% · 5 days −6.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Altimmune
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $19.00 at a price of $2.86 (+564.3%); now: $19.00 at $2.20 (+763.6%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 7 | 5 | 3 | 2 |
| Buy | 2 | 2 | 3 | 1 | 1 | 0 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.13 (from $-0.15 to $-0.11). Last quarter: $-0.12.
Sales
Next quarter’s sales estimate — $0M (from $0M to $0M). Last quarter: $0M.
Best top-analyst consensus in the sector · Healthcare
About Altimmune
- CEO: Jerome Benedict Durso
- Employees: 57
- 910 Clopper Road, Gaithersburg, MD, 20878, US
- altimmune.com
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Data from the stock’s TipRanks forecast page, read 106 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗